Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Temazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.59 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.59 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.59 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.59 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.59 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.59 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.59 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.59 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.59 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.59 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.59 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.59 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.59 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.59 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.59 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temazepam SCHEMBL29398512 | 1.00 | OPRK1 (1.00) | OPRK1LMNAPDE3APDE4DCHRM2 | |
| Temazepam SCHEMBL5503177 | 1.00 | OPRK1 (1.00) | OPRK1LMNAPDE3APDE4DCHRM2 | |
| Temazepam SCHEMBL81963 | 1.00 | OPRK1 (1.00) | OPRK1LMNAPDE3APDE4DCHRM2 | |
| Temazepam SCHEMBL29464 | 1.00 | OPRK1 (1.00) | OPRK1LMNAPDE3APDE4DCHRM2 | |
| Temazepam SCHEMBL16922195 | 1.00 | OPRK1 (1.00) | OPRK1LMNAPDE3APDE4DCHRM2 | |
| Temazepam SCHEMBL10480110 | 0.99 | OPRK1 (0.98) | OPRK1LMNAPDE3APDE4DCHRM2 | |
| Lormetazepam SCHEMBL1758605 | 0.93 | OPRK1 (0.89) | OPRK1LMNAPDE3APDE4DCHRM2 | |
| Temazepam SCHEMBL23038565 | 0.91 | OPRK1 (0.83) | OPRK1LMNAPDE3APDE4DCHRM2 | |
| Temazepam SCHEMBL8140373 | 0.91 | OPRK1 (0.83) | OPRK1LMNAPDE3APDE4DCHRM2 | |
| Temazepam SCHEMBL7036032 | 0.90 | OPRK1 (0.82) | OPRK1LMNAPDE3APDE4DCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 28171 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260108529-A1 | FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-19 | — | — | US | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| EP-0098113-A1 | A combination of beta-adrenoceptor antagonists and anxiolytic agents | AYERST, MCKENNA AND HARRISON INC. (CA) | 1984-01-11 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
| EP-0092179-A1 | Embedding unit of paving stones for producing soil covers, and process for producing the paving units and soil covers | Heinrich-Ludwig Wahrendorf oHG (DE) | 1983-10-26 | — | — | EP | claimed |
| EP-0081194-A1 | Bituminous pavement repair method | Schölkopf, Walter (DE) | 1983-06-15 | — | — | EP | claimed |
| EP-0072491-A1 | Brake for rolling containers | Lermer GmbH (DE) | 1983-02-23 | — | — | EP | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| EP-0060044-A1 | Fluidised bed combustion | EMS THERMPLANT LIMITED (GB) | 1982-09-15 | — | — | EP | claimed |
| US-4316897-A | TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1982-02-23 | — | — | US | claimed |
| EP-0025546-A2 | Therapeutical use of tranquillizing benzodiazepine derivatives and mixtures containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-03-25 | — | — | EP | claimed |
| US-4065451-A | CNS DEPRESSANTS | AMERICAN HOME PRODUCTS (US) | 1977-12-27 | — | — | US | claimed |